Stocks›Healthcare›NVO

NVO

NOVO NORDISK A/S

NYSEResearch view

Healthcare · Pharmaceutical Preparations · SEC EDGAR FY 2025-12-31

Price history

Chart: TradingView’s own feed · page prices: 1D EOD

🔒 Click to interact · scroll moves the page

The record

LAST 90 DAYS · 1D EOD

1 story has a settled receipt so far (1 on the Wire). The record starts speaking at three.

Jul 6Wegovy weight loss pill now available in UK - here's what you need to knowBBC Business−2.32%1D

Reaction = the first close after the story against the close before it. Prior-session closes only; not a call, not advice.

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Incomekr 102.4B

Saleskr 309.1B

Book/sh—

Cash/sh—

Dividend TTM—

Payout51%

Employees—

IPO—

Quick Ratio0.57

Current Ratio0.80

Debt/Eq0.67

EPS (ttm)kr 23.03

EPS this Y1.8%

EPS past 3/5Y23.5%

Sales past 3/5Y20.4%

EPS Y/Y TTM1.8%

Sales Y/Y TTM6.4%

Shs Outstand—

ROA18.9%

ROE52.8%

ROIC33.8%

Gross Margin81.0%

Oper. Margin41.3%

Profit Margin33.1%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue & Earnings — fiscal year

kr 140.8B

2021

kr 177.0B

2022

kr 232.3B

2023

kr 290.4B

2024

kr 309.1B

2025

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

DKK	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	kr 140.8B	kr 177.0B	kr 232.3B	kr 290.4B	kr 309.1B
Gross Profit	kr 117.1B	kr 148.5B	kr 196.5B	kr 245.9B	kr 250.3B
Operating Income	kr 58.6B	kr 74.8B	kr 102.6B	kr 128.3B	kr 127.7B
Net Income	kr 47.8B	kr 55.5B	kr 83.7B	kr 101.0B	kr 102.4B
Diluted EPS	kr 10.37	kr 12.22	kr 18.62	kr 22.63	kr 23.03
Operating Cash Flow	kr 55.0B	kr 78.9B	kr 108.9B	kr 121.0B	kr 119.1B
Free Cash Flow	kr 48.7B	kr 66.7B	kr 83.1B	kr 73.8B	kr 59.0B

Deep dive

Computed from the SEC EDGAR multi-year statements

Operating leverage — margins

GrossOperatingNet

FY25 cash-flow waterfall

Capital-light: capex is kr 60.1B against kr 119.1B operating cash

Follow the news. Track the move.

NVO story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

NVO direct/Earnings

Sep 17

Novo Nordisk (NVO) Pulls the Plug on Two More Heart Drug Trials

Novo Nordisk has stopped two additional heart-drug trials, adding to setbacks in its development pipeline. The move puts more pressure on the company’s existing portfolio and upcoming clinical milestones to support its growth story.

Price history unavailable

Yahoo Finance · 1d ago

View both sides →

Sector context/Earnings

Jul 6

Wegovy weight loss pill now available in UK - here's what you need to know

Novo Nordisk's oral weight-loss drug, Rybelsus (semaglutide), is now privately available in UK pharmacies, offering a pill alternative to the popular Wegovy injection. This expansion provides a more accessible option for patients seeking weight management, potentially broadening Novo Nordisk's market penetration in the UK.

Price history unavailable

BBC Business · 75d ago

View both sides →

Follow the news. Track the move.